Facebook
Google+
https://www.inovotion.com/publications/newsletter-2/newsletter-janvier-2021">
Twitter
LinkedIn

Here at INOVOTION we sincerely wish you all a Happy New Year from the entire team!

Here’s hoping that 2021 brings you joy through meaningful challenges, ambitious projects and partnerships, and ground-breaking accomplishments.

We look forward to working with you in the future.

We wish you all the best.

INOVOTION’s poster has been recognized as one of the 4 best posters at the AIS Congress 2020, 1st ex aequo in the industry category!

"Unique in vivo model in immuno-oncology for assessing efficacy of antibodies"

Congratulations to our Scientific and Technical Teams:

Xavier Rousset (R&D Team Manager),Emilien Dosda (Production Manager), Sylvain Roveda (Production Engineer), Yan WANG (R&D Project Manager) and Jean Viallet (CEO-CSO).

$ 1MILLION R&D CONTRACT AWARDED

High-potential biotech companies INOVOTION and LXRepair specialized in DNA repair assays have partnered with CHU Grenoble Alpes and the Institut for Avanced Biosciences (IAB) in a 900k€ R&D contract awarded by the Région Auvergne-Rhône-Alpes.

The project coordinated by INOVOTION’s R&D department will develop a disruptive new method for screening and validating new drugs, to widen and accelerate the development of new therapies for cancer and other diseases. The new method will also allow precision-medicine screening of patients, to select treatments based on their response to specific drugs.

If you also wish to collaborate with us, please, feel free to contact us.

BioTheryX, Inc. renews its confidence with INOVOTION for preclinical in vivo efficacy evaluation of their compounds.

For BioTheryX, Inc., a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, 2020 has been a fruitful year! The company launched a Phase 1 Clinical Trial of BTX-A51 in January and announced a $35 Million Series D financing in July. We are proud to contribute to BioTheryX, Inc. preclinical efforts!

Leah Fung, PhD, Head of Medicinal Chemistry

"We have found over the past few months and after several projects that INOVOTION’s CAM model is a cost-effective and rapid way to evaluate in vivo efficacy and toxicity of our small molecule #oncology candidates. INOVOTION took the time to understand our project needs and their experienced R&D team worked with us on project design and validation."

Aparajita Hoskote Chourasia, MS, PhD, Associate Director, Biology

"INOVOTION’s data reporting is very detailed and their project management team was always available to make necessary adjustments, discuss results in detail and design potential future steps. We appreciate the timeliness with which they completed our projects, the responsiveness of their communications. They are always ready to accommodate special requests."

If you also wish to collaborate with us, please, feel free to contact us.  

PRECLINICAL EVALUATION OF ANTIMETASTATIC DRUG CANDIDATES USING A NEXT-GENERATION CHICKEN EMBRYO MODEL

Metastasis is a complex disease with multiple stages and diverse signaling pathways. Despite intensive research to identify therapeutic targets and develop new antimetastatic drugs, it still remains the leading cause of cancer patient death. Several notable efforts have been made to develop antimetastatic drugs but have all failed (MMP inhibitors, anti-NF-kB, biphosphonates, etc). This is mainly because metastasis is a dynamic process, which is complex to model. Actual preclinical models are very often built for anti-proliferative drug development and do not recapitulate all steps in the metastatic process.

Moreover, the biology of metastatic cells differs completely from primary tumor cells. It is therefore necessary to rethink existing preclinical models and determine new endpoints that properly evaluate their antimetastatic properties in designing new drugs to prevent or delay metastatis.

The mouse is the most commonly used preclinical model for evaluating newly developed antimetastatic compounds. However, its efficiency is limited by factors such as the presence/absence of an immune system, the site of injection or the presence/absence of a primary tumor. The chicken embryo model presents the advantage of recapitulating all steps of spontaneous metastasis in 9 days including the formation of a primary tumor, intravasation, extravasation from the vasculature and establishment at distant sites.

UPCOMING EVENTS WHERE YOU CAN MEET US:

- DIGITAL PREDICT TUMOR MODELS FOR IMMUNO-ONCOLOGY SUMMIT 

26-28 January

 

- WORLD ADC EUROPE DIGITAL 2021 

8-11 March 

 

- DIGITAL BIOEUROPE SPRING 

22-25 March

ABOUT US 

Optimizing your preclinical and Drug Discovery studies is of prime importance, and INOVOTION has developed a solution based on its unique and cutting-edge in vivo technology.

As a Contract Research Organization (CRO) dedicated to in vivo evaluation for Drug Discovery mainly in oncology and immuno-oncology, INOVOTION is a sought-after partner for Pharma and Biotech companies as well as academic labs all over the world.

Our main missions are to:

  • Help you find the best candidate anti-cancer treatment
  • Detect the first in vivo toxicity effects of your candidate compounds
  • Improve productivity and Return-On-Investment of your preclinical and Drug Discovery process by maximizing your lead optimization phase 
  • Accelerate the overall Drug Discovery process to answer unmet medical needs in oncology.

Any questions about Inovotion's technology? 

Contact us at : contact@inovotion.com

INOVOTION SAS
HQ & Lab Facilities

+33 475 549 512

5 ave du Grand Sablon
38700 La Tronche
France

INOVOTION Inc

185 Alewife Brook Parkway, Suite 210
Cambridge, MA 02138

USA

Facebook
Google+
https://www.inovotion.com/publications/newsletter-2/newsletter-janvier-2021">
Twitter
LinkedIn

Register for our Newsletter